Bioinformatics Analysis Reveals Potential Candidate Drugs for HCC
- PDF / 362,567 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 54 Downloads / 227 Views
RESEARCH
Bioinformatics Analysis Reveals Potential Candidate Drugs for HCC Xiao-Bing Huang & Jing Li & Lu Zheng & Guo-Hua Zuo & Ke-Qiang Han & Hong-Yan Li & Ping Liang
Received: 13 June 2012 / Accepted: 24 September 2012 / Published online: 23 January 2013 # Arányi Lajos Foundation 2013
Abstract In our study, we used the GSE17967 series to identify differentially expressed genes between cirrhosis and hepatocellular carcinoma, aiming to analyse the mechanism of the progression of cirrhosis to hepatocellular carcinoma and identify the sub-pathways closely related to this progression, and find the small molecule drugs to interfere this progression. From the result of our study, we find that many small molecule drugs closely related with carcinoma have been linked by our method. We also find some new small molecule drugs related to this progression. It is demonstrated that bioinformatics analysis is useful in identification of the candidate drugs in hepatocellular carcinoma. Keywords Hepatocellular carcinoma . Cirrhosis . Sub-pathways . Small molecule drugs
Introduction Hepatocellular carcinoma is the fifth most common cancer worldwide and the most common form of liver cancer, being responsible for 80 % of the primary malignant liver tumors in adults [1, 2]. The 5-year relative survival rate is about 7 % and causes more than 6 million deaths annually worldwide [1].
Electronic supplementary material The online version of this article (doi:10.1007/s12253-012-9576-y) contains supplementary material, which is available to authorized users. X.-B. Huang : J. Li : L. Zheng : G.-H. Zuo : K.-Q. Han : H.-Y. Li : P. Liang (*) Department of Hepatobiliary Surgery, Xinqiao Hospital, Third Military Medical University, 400037, NO.2 Xin Qiao Street, Sha Ping Ba District, Chongqing, People’s Republic of China e-mail: [email protected]
The disease is most prevalent in Eastern and Southeastern Asia, and Middle Africa, with more than half of the patients being reported from China [2, 3]. Much is known about the development and causes of HCC. Patients with cirrhosis of the liver have been identified as being at risk for hepatocellular carcinoma, and hepatocellular carcinoma is the principal cause of death in patients with cirrhosis. It is unclear why this tumor frequently accompanies cirrhosis [5–7]. Hepatocellular carcinoma may be either the inevitable consequence of longstanding hepatic disease or an independent response to a hepatic insult common to hepatocellular carcinoma and cirrhosis [4]. Although the importance of the association of hepatocellular carcinoma with cirrhosis is still obscure, such an association provides a means to identify patients at high risk for hepatocellular carcinoma [5]. Even in developed countries, potentially curative therapies are offered to only one in every four patients coming to highly committed centers [10, 11]. Curative therapies, such as resection, liver transplantation, or percutaneous treatments, benefit only 25 % of patients and are the only chance to improve life expectancy. Despite t
Data Loading...
